Shilpa Medicare
Shilpa Medicare Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Shilpa Medicare Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Shilpa Medicare Ltd trades at a P/E of 43.92× and P/B of 4.13×.
Valuation
Profitability
Growth
Financial Health
Shilpa Medicare Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Shilpa Medicare Ltd, switchable between annual and quarterly views, consolidated or standalone.
Shilpa Medicare Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹10,698.33 Cr and reported EPS of ₹12.45.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 792 | 733 | 908 | 901 | 1,146 | 1,050 | 1,152 | 1,286 | 1,539 |
| Other Income | 22 | 14 | 17 | 30 | 14 | 17 | 8 | 23 | 10 |
| Total Income | 813 | 747 | 925 | 931 | 1,160 | 1,068 | 1,160 | 1,310 | 1,549 |
| Cost of Goods Sold (COGS) | 356 | 257 | 278 | 271 | 383 | 416 | 408 | 410 | 460 |
| Gross Profit | 436 | 477 | 630 | 630 | 762 | 634 | 744 | 876 | 1,078 |
| +Operating Expenses | 273 | 321 | 410 | 449 | 558 | 532 | 500 | 559 | 644 |
| EBITDA | 162 | 156 | 220 | 182 | 204 | 102 | 244 | 317 | 435 |
| +Non-Operating Expenses | 40 | 66 | 48 | 135 | 126 | 154 | 206 | 160 | 208 |
| Profit Before Tax (PBT) | 144 | 144 | 188 | 195 | 102 | -34 | 59 | 124 | 295 |
| +Tax Expense | 34 | 26 | 33 | 49 | 42 | -7 | 22 | 44 | 52 |
| Profit After Tax (PAT) | 103 | 110 | 156 | 146 | 61 | -32 | 32 | 78 | 243 |
| Earnings Per Share (EPS) | 6.45 | 6.88 | 9.58 | 9.06 | 3.49 | -1.87 | 1.84 | 4.00 | 12.44 |
| Diluted Shares Outstanding (Nos.) | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 20 | 20 |
| +Additional Disclosures | 1,017 | 870 | 1,015 | 1,068 | 1,445 | 1,516 | 1,507 | 1,565 | 1,743 |
| Sales Growth % | — | -7.35 | 23.80 | -0.75 | 27.12 | -8.33 | 9.66 | 11.71 | 19.62 |
| YoY Sales Growth % | — | -7.35 | 23.80 | -0.75 | 27.12 | -8.33 | 9.66 | 11.71 | 19.62 |
| Material Cost % | 39 | 34 | 32 | 35 | 33 | 35 | 37 | 27 | 31 |
| Employee Cost % | 19 | 24 | 22 | 26 | 23 | 27 | 24 | 23 | 22 |
| Other Cost % | 16 | 20 | 24 | 24 | 26 | 23 | 19 | 21 | 20 |
| OPM % | 20 | 21 | 24 | 20 | 18 | 10 | 21 | 25 | 28 |
| Tax % | 24 | 18 | 18 | 25 | 41 | 21 | 38 | 36 | 18 |
| Profit Growth % | — | 6.46 | 42.60 | -6.37 | -58.56 | -153.61 | 198.15 | 145.63 | 210.79 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 125 | 114 | 176 | 128 | 124 | 7 | 137 | 204 | 315 |
Shilpa Medicare segment analysis: revenue and profit mix.
Disclosed business segments at Shilpa Medicare with their share of revenue and profit, switchable between consolidated and standalone reporting.
Shilpa Medicare discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Shilpa Medicare Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Shilpa Medicare Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Shilpa Medicare Ltd's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust quarterly profit growth of 234.00% indicates strong operational performance.
Healthy quarterly sales growth of 9.90% reflects sustained market demand.
Low debt-to-equity ratio of 0.25 signifies a strong financial position.
Solid operating profit margin of 25.40% highlights efficient cost management.
Diverse oncology and non-oncology API portfolio with global market reach.
What can break it.
High P/E ratio of 66.73 suggests potential overvaluation compared to earnings.
Low Return on Equity (ROE) of 1.38% indicates inefficient shareholder capital utilization.
Negative 5-year EPS growth of -15.85% raises concerns about long-term profitability.
Declining promoter holding from 50.01% to 44.23% may impact investor confidence.
Zero dividend yield (0.00%) makes the stock unattractive for income investors.
What would change my mind.
Trim if P/E re-rates above 57. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 25.97. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 8%. The operating engine is no longer compounding capital efficiently.
Shilpa Medicare Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Shilpa Medicare Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Shilpa Medicare Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Shilpa Medicare Ltd — derived from the live tape, not yesterday's close.
Shilpa Medicare Ltd last traded at ₹546.75 with an intraday range of ₹538.2–₹556.75 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹546.75| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 593.37 | +46.62 | +8.53% |
| R3 | 574.82 | +28.07 | +5.13% |
| R2 | 565.78 | +19.03 | +3.48% |
| R1 | 556.27 | +9.52 | +1.74% |
| PIVOT | 547.23 | 0.48 | 0.09% |
| CURRENT | 546.75 | — | — |
| S1 | 500.62 | -46.13 | -8.44% |
| S2 | 519.17 | -27.58 | -5.04% |
| S3 | 528.68 | -18.07 | -3.30% |
| S4 | 537.72 | -9.03 | -1.65% |
SHILPAMED is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: 548 ~ 556.75
Trading Inside opening range
Shilpa Medicare Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Shilpa Medicare Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Shilpa Medicare Ltd stood at 46.1% of traded volume, against a 20-day average of 40.7%.
Shilpa Medicare announcements: results, concalls, ratings, M&A.
Filings Shilpa Medicare sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Shilpa Medicare files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 139 documents below.
Press Release
Shilpa Medicare Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Shilpa Biocare Pvt Ltd, a Wholly owned…
General Updates
Shilpa Medicare Limited has informed the Exchange about USFDA Inspection at Unit VI, Dabaspet, Bengaluru
Analysts/Institutional Investor Meet/Con. Call Updates
Shilpa Medicare Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Shilpa Medicare Limited has informed the Exchange about Copy of Newspaper Publication regarding Postal Ballot notice of the Company.
Investor Presentation
Shilpa Medicare Limited has informed the Exchange about Investor Presentation
Investor decks & rating reports.
Shilpa Medicare dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Shilpa Medicare has declared, sequenced by announce and record date.
Shilpa Medicare corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Shilpa Medicare Ltd: business, sector, key facts.
What Shilpa Medicare Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Shilpa Medicare Ltd operates in the Healthcare, listed as NSE: SHILPAMED, BSE: 530549.
Shilpa Medicare Limited is a pharmaceutical company headquartered in Raichur, India, with a global reach encompassing the United States and Europe. The company's core business is the manufacture and sale of active pharmaceutical ingredients (APIs) and finished dosage formulations. Their extensive API portfolio caters to both oncology and non-oncology treatments, including a wide range of molecules like anastrozole, azacitidine, bortezomib, capecitabine, dasatinib, and many others, showcasing their capabilities in producing complex and specialized chemical compounds. They also offer a significant array of intermediates, high-purity peptides, specialty and biopolymers, and biologics.
Beyond APIs, Shilpa Medicare's capabilities extend to the manufacturing of diverse finished dosage formulations. These include a variety of delivery systems such as tablets, capsules, liquid and dry powder injections, orally disintegrating films, transdermal patches, and lyophilized injectables. Their specialization in oncology formulations highlights a key area of focus within their product offerings. This broad range of formulations caters to different patient needs and administration preferences, showcasing a commitment to diverse pharmaceutical delivery methods.
The company provides contract development and manufacturing services (CDMO), indicating a willingness to partner with other pharmaceutical companies to produce their products. This aspect of their business demonstrates a capacity to leverage their expertise and manufacturing infrastructure to support other players in the industry. Additionally, Shilpa Medicare is involved in wind power generation, indicating diversification beyond their core pharmaceutical operations.
In summary, Shilpa Medicare's business model combines the manufacturing and sale of a vast array of APIs and finished dosage formulations, with a focus on oncology treatments, complemented by CDMO services and diversification into renewable energy. This multifaceted approach establishes a robust and diverse pharmaceutical and energy company with a strong international presence.
Questions investors ask about Shilpa Medicare Ltd (SHILPAMED).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Shilpa Medicare Ltd (SHILPAMED)?
The current share price of Shilpa Medicare Ltd (SHILPAMED) is ₹546.75. Today, the stock has gained by ₹7.90 (1.47%), trading in a range of ₹538.2 to ₹556.75. The stock opened at ₹549.9 with a trading volume of 6,55,163 shares.
02Is Shilpa Medicare Ltd stock a good investment for long-term?
Shilpa Medicare Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹10,698.33 crores, P/E ratio of 43.92, ROE of 9.82%, and ROCE of 7.82%. The dividend yield stands at 0.09%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Shilpa Medicare Ltd stock?
The 52-week high price of Shilpa Medicare Ltd (SHILPAMED) is ₹0, while the 52-week low is ₹0. Currently trading at ₹546.75, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Shilpa Medicare Ltd stock at the current price?
Whether to buy Shilpa Medicare Ltd stock at ₹546.75 depends on multiple factors. The stock is currently trading with a P/E ratio of 43.92 and P/B ratio of 4.13. Today's performance shows a gain of 1.47%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Shilpa Medicare Ltd and when is the next dividend?
Shilpa Medicare Ltd offers a dividend yield of 0.09%, which means for every ₹100 invested at the current price of ₹546.75, you can expect to receive approximately ₹0.09 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Shilpa Medicare Ltd?
Shilpa Medicare Ltd's key financial metrics include: P/E Ratio: 43.92, P/B Ratio: 4.13, ROE: 9.82%, ROCE: 7.82%, Dividend Yield: 0.09%, EPS: ₹12.45, Book Value: ₹132.46, and Debt-to-Equity: 25.47. The company's market cap stands at ₹10,698.33 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Shilpa Medicare Ltd stock performing today in the market?
Shilpa Medicare Ltd stock opened at ₹549.9 and is currently trading at ₹546.75, showing a gain of ₹7.90 (1.47%). The intraday high is ₹556.75 and low is ₹538.2. The trading volume stands at 6,55,163 shares, indicating moderate market participation today.
08What is the P/E ratio of Shilpa Medicare Ltd and what does it indicate?
Shilpa Medicare Ltd has a Price-to-Earnings (P/E) ratio of 43.92, which means investors are willing to pay ₹43.92 for every ₹1 of earnings. With an EPS of ₹12.45, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Shilpa Medicare Ltd (SHILPAMED) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy